Deniz Bagdas1, Katarzyna M Targowska-Duda, Jhon J López, Edwin G Perez, Hugo R Arias, M Imad Damaj. 1. From the *Department of Pharmacology and Toxicology, Medical College of Virginia Campus, Virginia Commonwealth University, Richmond, Virginia; †Experimental Animals Breeding and Research Center, Faculty of Medicine, Uludag University, Bursa, Turkey; ‡Department of Biopharmacy, Laboratory of Medicinal Chemistry and Neuroengineering, Medical University of Lublin, Lublin, Poland; §Faculty of Chemistry, Department of Organic Chemistry, Pontificia Universidad Católica de Chile, Santiago, Chile; and ‖Department of Medical Education, California Northstate University College of Medicine, Elk Grove, California.
Abstract
BACKGROUND: Positive allosteric modulators (PAMs) facilitate endogenous neurotransmission and/or enhance the efficacy of agonists without directly acting on the orthosteric binding sites. In this regard, selective α7 nicotinic acetylcholine receptor type II PAMs display antinociceptive activity in rodent chronic inflammatory and neuropathic pain models. This study investigates whether 3-furan-2-yl-N-p-tolyl-acrylamide (PAM-2), a new putative α7-selective type II PAM, attenuates experimental inflammatory and neuropathic pains in mice. METHODS: We tested the activity of PAM-2 after intraperitoneal administration in 3 pain assays: the carrageenan-induced inflammatory pain, the complete Freund adjuvant-induced inflammatory pain, and the chronic constriction injury-induced neuropathic pain in mice. We also tested whether PAM-2 enhanced the effects of the selective α7 agonist choline in the mouse carrageenan test given intrathecally. Because the experience of pain has both sensory and affective dimensions, we also evaluated the effects of PAM-2 on acetic acid-induced aversion by using the conditioned place aversion test. RESULTS: We observed that systemic administration of PAM-2 significantly reversed mechanical allodynia and thermal hyperalgesia in inflammatory and neuropathic pain models in a dose- and time-dependent manner without motor impairment. In addition, by attenuating the paw edema in inflammatory models, PAM-2 showed antiinflammatory properties. The antinociceptive effect of PAM-2 was inhibited by the selective competitive antagonist methyllycaconitine, indicating that the effect is mediated by α7 nicotinic acetylcholine receptors. Furthermore, PAM-2 enhanced the antiallodynic and antiinflammatory effects of choline, a selective α7 agonist, in the mouse carrageenan test. PAM-2 was also effective in reducing acetic acid-induced aversion in the conditioned place aversion assay. CONCLUSIONS: These findings suggest that the administration of PAM-2, a new α7-selective type II PAM, reduces the neuropathic and inflammatory pain sensory and affective behaviors in the mouse. Thus, this drug may have therapeutic applications in the treatment and management of chronic pain.
BACKGROUND: Positive allosteric modulators (PAMs) facilitate endogenous neurotransmission and/or enhance the efficacy of agonists without directly acting on the orthosteric binding sites. In this regard, selective α7 nicotinic acetylcholine receptor type II PAMs display antinociceptive activity in rodent chronic inflammatory and neuropathic pain models. This study investigates whether 3-furan-2-yl-N-p-tolyl-acrylamide (PAM-2), a new putative α7-selective type II PAM, attenuates experimental inflammatory and neuropathic pains in mice. METHODS: We tested the activity of PAM-2 after intraperitoneal administration in 3 pain assays: the carrageenan-induced inflammatory pain, the complete Freund adjuvant-induced inflammatory pain, and the chronic constriction injury-induced neuropathic pain in mice. We also tested whether PAM-2 enhanced the effects of the selective α7 agonist choline in the mousecarrageenan test given intrathecally. Because the experience of pain has both sensory and affective dimensions, we also evaluated the effects of PAM-2 on acetic acid-induced aversion by using the conditioned place aversion test. RESULTS: We observed that systemic administration of PAM-2 significantly reversed mechanical allodynia and thermal hyperalgesia in inflammatory and neuropathic pain models in a dose- and time-dependent manner without motor impairment. In addition, by attenuating the paw edema in inflammatory models, PAM-2 showed antiinflammatory properties. The antinociceptive effect of PAM-2 was inhibited by the selective competitive antagonist methyllycaconitine, indicating that the effect is mediated by α7 nicotinic acetylcholine receptors. Furthermore, PAM-2 enhanced the antiallodynic and antiinflammatory effects of choline, a selective α7 agonist, in the mousecarrageenan test. PAM-2 was also effective in reducing acetic acid-induced aversion in the conditioned place aversion assay. CONCLUSIONS: These findings suggest that the administration of PAM-2, a new α7-selective type II PAM, reduces the neuropathic and inflammatory pain sensory and affective behaviors in the mouse. Thus, this drug may have therapeutic applications in the treatment and management of chronic pain.
Authors: Beatriz Balsera; José Mulet; Asia Fernández-Carvajal; Roberto de la Torre-Martínez; Antonio Ferrer-Montiel; José G Hernández-Jiménez; Judith Estévez-Herrera; Ricardo Borges; Andiara E Freitas; Manuela G López; M Teresa García-López; Rosario González-Muñiz; María Jesús Pérez de Vega; Luis M Valor; Lucie Svobodová; Salvador Sala; Francisco Sala; Manuel Criado Journal: Eur J Med Chem Date: 2014-09-16 Impact factor: 6.514
Authors: Deniz Bagdas; Jenny L Wilkerson; Abhijit Kulkarni; Wisam Toma; Shakir AlSharari; Zulfiye Gul; Aron H Lichtman; Roger L Papke; Ganesh A Thakur; M Imad Damaj Journal: Br J Pharmacol Date: 2016-07-18 Impact factor: 8.739
Authors: Giulia Donvito; Deniz Bagdas; Wisam Toma; Elnaz Rahimpour; Asti Jackson; Julie A Meade; Shakir AlSharari; Abhijit R Kulkarni; F Ivy Carroll; Aron H Lichtman; Roger L Papke; Ganesh A Thakur; M Imad Damaj Journal: Exp Neurol Date: 2017-06-09 Impact factor: 5.330
Authors: Eslam Gaber El Nebrisi; Deniz Bagdas; Wisam Toma; Halima Al Samri; Anna Brodzik; Yasmin Alkhlaif; Keun-Hang Susan Yang; Frank Christopher Howarth; Imad M Damaj; Murat Oz Journal: J Pharmacol Exp Ther Date: 2018-01-16 Impact factor: 4.030